Intercept Pharmaceut (ICPT) 150.74 $ICPT Interc
Post# of 273258
Posted On: 09/02/2016 7:17:23 PM
Intercept Pharmaceut (ICPT) 150.74 $ICPT
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Sep 02, 6:30AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 150.74 (+3.92)
Intercept (ICPT) Ocaliva Phase III POISE Data Published
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:12AM CDT
Intercept Pharmaceuticals (ICPT) announced the publication of phase III POISE study data on Ocaliva for the treatment primary biliary cholangitis.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ICPT: 150.74 (+3.92)
New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva(R) (Obeticholic Acid) for the Treatment of PBC
GlobeNewswire - Wed Aug 17, 4:07PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the New England Journal of Medicine published the key results of the Phase 3 POISE trial of Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis, formerly known as primary biliary cirrhosis (PBC). On a background of standard of care or given as monotherapy, Ocaliva met the primary endpoint of the POISE trial and improved multiple biochemical disease markers as compared to placebo with high statistical significance.
ICPT: 150.74 (+3.92)
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.14 (-0.05), BIIB: 313.59 (+7.56), ICPT: 150.74 (+3.92)
Intercept (ICPT) Posts Narrower-Than-Expected Loss in Q2
Ekta Bagri - Zacks Investment Research - Thu Aug 04, 7:39AM CDT
Intercept (ICPT) reported a narrower-than-expected loss of $3.76 in the second-quarter of 2016.
ICPT: 150.74 (+3.92)
Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma
PR Newswire - Thu Aug 04, 7:20AM CDT
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
CERS: 6.36 (unch), TSRO: 84.87 (+0.52), ICPT: 150.74 (+3.92), FPRX: 43.71 (-1.03)
Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Thu Aug 04, 6:05AM CDT
-- Ocaliva (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016
ICPT: 150.74 (+3.92)
Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:26AM CDT
GW Pharmaceuticals (GWPH), which is is set to report third-quarter fiscal 2016 results on Aug 4, had posted a positive surprise of 35.67% last quarter.
BMRN: 95.73 (+0.54), GWPH: 82.73 (+0.45), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), EXEL: 11.54 (+0.19), CELG: 105.49 (-0.88)
Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:26AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report second-quarter 2016 results on Aug 4, after the market closes.
IPXL: 24.03 (+0.09), IRWD: 13.26 (-0.09), ICPT: 150.74 (+3.92), MYL: 39.97 (-1.95)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.26 (+0.15), ABT: 42.09 (-0.21), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 95.73 (+0.54), PFE: 34.77 (+0.09), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
GlobeNewswire - Thu Jul 28, 6:06AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results.
ICPT: 150.74 (+3.92)
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Intercept Pharmaceuticals, Inc. Securities Litigation
PR Newswire - Mon Jun 20, 10:30AM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Intercept Pharmaceuticals, Inc. Securities Litigation:
ICPT: 150.74 (+3.92)
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 150.74 (+3.92)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 313.59 (+7.56), SRPT: 26.89 (+0.33), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09), IONS: 29.46 (-0.58)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), GILD: 76.89 (-0.53), SRPT: 26.89 (+0.33), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09), IONS: 29.46 (-0.58)
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Sep 02, 6:30AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 150.74 (+3.92)
Intercept (ICPT) Ocaliva Phase III POISE Data Published
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:12AM CDT
Intercept Pharmaceuticals (ICPT) announced the publication of phase III POISE study data on Ocaliva for the treatment primary biliary cholangitis.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ICPT: 150.74 (+3.92)
New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva(R) (Obeticholic Acid) for the Treatment of PBC
GlobeNewswire - Wed Aug 17, 4:07PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the New England Journal of Medicine published the key results of the Phase 3 POISE trial of Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis, formerly known as primary biliary cirrhosis (PBC). On a background of standard of care or given as monotherapy, Ocaliva met the primary endpoint of the POISE trial and improved multiple biochemical disease markers as compared to placebo with high statistical significance.
ICPT: 150.74 (+3.92)
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.14 (-0.05), BIIB: 313.59 (+7.56), ICPT: 150.74 (+3.92)
Intercept (ICPT) Posts Narrower-Than-Expected Loss in Q2
Ekta Bagri - Zacks Investment Research - Thu Aug 04, 7:39AM CDT
Intercept (ICPT) reported a narrower-than-expected loss of $3.76 in the second-quarter of 2016.
ICPT: 150.74 (+3.92)
Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma
PR Newswire - Thu Aug 04, 7:20AM CDT
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
CERS: 6.36 (unch), TSRO: 84.87 (+0.52), ICPT: 150.74 (+3.92), FPRX: 43.71 (-1.03)
Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Thu Aug 04, 6:05AM CDT
-- Ocaliva (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016
ICPT: 150.74 (+3.92)
Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:26AM CDT
GW Pharmaceuticals (GWPH), which is is set to report third-quarter fiscal 2016 results on Aug 4, had posted a positive surprise of 35.67% last quarter.
BMRN: 95.73 (+0.54), GWPH: 82.73 (+0.45), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), EXEL: 11.54 (+0.19), CELG: 105.49 (-0.88)
Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:26AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report second-quarter 2016 results on Aug 4, after the market closes.
IPXL: 24.03 (+0.09), IRWD: 13.26 (-0.09), ICPT: 150.74 (+3.92), MYL: 39.97 (-1.95)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.26 (+0.15), ABT: 42.09 (-0.21), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 95.73 (+0.54), PFE: 34.77 (+0.09), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Intercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference
GlobeNewswire - Thu Jul 28, 6:06AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ market open on Thursday, August 4, 2016. Intercept management will conduct a conference call and audio webcast on Thursday, August 4, 2016 at 8:30 a.m. Eastern Time to discuss these results.
ICPT: 150.74 (+3.92)
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Intercept Pharmaceuticals, Inc. Securities Litigation
PR Newswire - Mon Jun 20, 10:30AM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Intercept Pharmaceuticals, Inc. Securities Litigation:
ICPT: 150.74 (+3.92)
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 150.74 (+3.92)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 313.59 (+7.56), SRPT: 26.89 (+0.33), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09), IONS: 29.46 (-0.58)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), GILD: 76.89 (-0.53), SRPT: 26.89 (+0.33), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09), IONS: 29.46 (-0.58)
(0)
(0)Scroll down for more posts ▼